VYTORIN 10-80 (ezetimibe/simvastatin)
ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS) · HYPERCHOLESTEROLEMIA ·+4
ORGANON LLC
Drug class
Antihyperlipidemics HMGCo-A Reductase Inhibitors (Statins)
Antihyperlipidemics: HMG-CoA reductase inhibitors, commonly referred to as statins, are a foundational class of lipid-lowering therapeutic agents. Read more about Antihyperlipidemics HMGCo-A Reductase Inhibitors (Statins)
195 drugs in this class 87 manufacturers
Drugs in Antihyperlipidemics HMGCo-A Reductase Inhibitors (Statins)
ROSZET (ezetimibe/rosuvastatin calcium)
ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS) · HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA ·+1
ALTHERA PHARMAC
CADUET (amlodipine besylate/atorvastatin calcium)
CALCIUM CHANNEL BLOCKERS · HYPERCHOLESTEROLEMIA ·+13
Laboratories Div
ATORVALIQ (atorvastatin calcium)
ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS) · HYPERCHOLESTEROLEMIA ·+11
CAROLINA MED.
LIPITOR (atorvastatin calcium)
ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS) · HYPERCHOLESTEROLEMIA ·+11
VIATRIS SPECIAL
PITAVASTATIN CALCIUM
ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS) · HYPERCHOLESTEROLEMIA ·+2
Upsher-Smith Laboratories
PITAVASTATIN CALCIUM
ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS) · HYPERCHOLESTEROLEMIA ·+2
Mylan Pharmaceuticals
FLUVASTATIN ER (fluvastatin sodium)
ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS) · HYPERCHOLESTEROLEMIA ·+5
Lannett Company
LOVASTATIN
ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS) · HYPERCHOLESTEROLEMIA ·+7
BLENHEIM PHARMA
Filter & compare in the drug finder →
Opens the drug finder with Antihyperlipidemics HMGCo-A Reductase Inhibitors (Statins) preselected. Add indication or manufacturer filters there.
Antihyperlipidemics: HMG-CoA reductase inhibitors, commonly referred to as statins, are a foundational class of lipid-lowering therapeutic agents.
They function by competitively inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in hepatic cholesterol biosynthesis, which triggers an upregulation of hepatic low-density lipoprotein (LDL) receptors and accelerates the clearance of circulating atherogenic lipoproteins.
Clinically, these medications are primarily prescribed to treat primary hyperlipidemia and mixed dyslipidemia, as well as for the primary and secondary prevention of atherosclerotic cardiovascular disease, including myocardial infarction and ischemic stroke.
-
nih.gov
Antihyperlipidemics: HMG-CoA reductase inhibitors, commonly referred to as statins, are a foundational class of lipid-lowering therapeutic agents Clinically, these medications are primarily prescribed to treat primary hyperlipidemia and mixed dyslipidemia, as well as for the primary and secondary prevention of atherosclerotic cardiovascular disease, including myocardial infarction and ischemic stroke
-
nih.gov
Antihyperlipidemics: HMG-CoA reductase inhibitors, commonly referred to as statins, are a foundational class of lipid-lowering therapeutic agents They function by competitively inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in hepatic cholesterol biosynthesis, which triggers an upregulation of hepatic low-density lipoprotein (LDL) receptors and accelerates the clearance of circulating atherogenic lipoproteins
-
nih.gov
They function by competitively inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in hepatic cholesterol biosynthesis, which triggers an upregulation of hepatic low-density lipoprotein (LDL) receptors and accelerates the clearance of circulating atherogenic lipoproteins
-
nih.gov
Clinically, these medications are primarily prescribed to treat primary hyperlipidemia and mixed dyslipidemia, as well as for the primary and secondary prevention of atherosclerotic cardiovascular disease, including myocardial infarction and ischemic stroke
-
nih.gov
Clinically, these medications are primarily prescribed to treat primary hyperlipidemia and mixed dyslipidemia, as well as for the primary and secondary prevention of atherosclerotic cardiovascular disease, including myocardial infarction and ischemic stroke
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.